UC Davis Health Ventures, part of the Innovation and Economic Development Office (IEDO) at the University of California, Davis, today announced the first investment from its Investing in the Future of Medicine (IFM) Fund, backing Delix Therapeutics.

Delix Therapeutics recently announced that the first neuroplastogen drug based on UC Davis Institute for Psychedelics and Neurotherapeutics (IPN) research will be tested in patients with major depressive disorder.